Figure 1
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) study flowchart and the number of individuals at each stage of the study.
1 We only included those treated (class 1–2) at a single institution to ensure data consistency.
2 Sixth (2007–2009) or Seventh (2010–2013) American Joint Committee on Cancer.
3 60–70 Gy in 1.8–2 Gy/fraction, ±10% in dose.
4 Dose/fraction compatible with National Comprehensive Cancer Network non-small cell lung cancer guideline 2017 v8 (i.e., 25–34 Gy/1 fraction, or 45–60 Gy/3 fractions, or 48–50 Gy/4 fractions, or 50–55 Gy/5 fractions, or 60–70 Gy/8–10 fractions), ±10% in dose.
5Adenocarcinoma or non-adenocarcinoma.
6 Without missing information in the Taiwan cancer registry and death registry.
Table 1
Patient characteristics for the whole study population
| SABR | CFRT | Standardized difference (rounded)* | |||||
|---|---|---|---|---|---|---|---|
| Number or mean (sd)* | (%)* | Number or mean (sd)* | (%)* | Before IPW | After | ||
| Age | 77.81 (7.85) | 75.40 (9.96) | 0.27 | 0.24 | |||
| Sex | Female | 20 | (29) | 44 | (26) | 0.07 | 0.07 |
| Male | 49 | (71) | 125 | (74) | |||
| Residency | Non-north | 32 | (46) | 93 | (55) | 0.17 | 0.19 |
| North | 37 | (54) | 76 | (45) | |||
| Comorbidity | Without | 9 | (13) | 43 | (25) | 0.32 | 0.25 |
| With† | 60 | (87) | 126 | (75) | |||
| Histology | Adenocarcinoma | 40 | (58) | 82 | (49) | 0.19 | 0.24 |
| Non-adenocarcinoma | 29 | (42) | 87 | (51) | |||
| T stage | T1 | 38 | (55) | 49 | (29) | 0.55 | 0.08 |
| T2 | 31 | (45) | 120 | (71) | |||
| Period | 2007–2009 | 15 | (22) | 65 | (38) | 0.37 | 0.22 |
| 2010–2013 | 54 | (78) | 104 | (62) | |||
| Use of PET | Yes | 37 | (54) | 55 | (33) | 0.44 | 0.09 |
| No | 32 | (46) | 114 | (67) | |||
| Use of systemic therapy | Yes | 10 | (14) | 73 | (43) | 0.67 | 0.17 |
| No | 59 | (86) | 96 | (57) | |||
| Previous cancer | Yes | 9 | (13) | 16 | (9) | 0.11 | 0.06 |
| No | 60 | (87) | 153 | (91) | |||
CFRT = conventional fractionated radiotherapy; IPW = inverse probability weighting; PET = positron emission tomography; SABR = stereotactic ablative radiotherapy; sd = standard deviation;
Figure 2
Kaplan-Meier survival curve for the whole study population.
CFRT = conventional fractionated radiotherapy; SABRT = stereotactic ablative radiotherapy
Table 2
Patient characteristics in the first supplementary analysis
| SABR | CFRT | |||||
|---|---|---|---|---|---|---|
| Number or mean (sd)* | (%)* | Number or mean (sd)* | (%)* | |||
| Age | 77.47 (8.26) | 77.75 (9.79) | 0.03 | |||
| Sex | Female | 18 | (30) | 24 | (40) | 0.21 |
| Male | 42 | (70) | 36 | (60) | ||
| Residency | Non-north | 29 | (48) | 30 | (50) | 0.03 |
| North | 31 | (52) | 30 | (50) | ||
| Comorbidity | Without | 9 | (15) | 8 | (13) | 0.05 |
| With† | 51 | (85) | 52 | (87) | ||
| Histology | Adenocarcinoma | 37 | (62) | 41 | (68) | 0.14 |
| Non-adenocarcinoma | 23 | (38) | 19 | (32) | ||
| T stage | T1 | 30 | (50) | 31 | (52) | 0.03 |
| T2 | 30 | (50) | 29 | (48) | ||
| Period | 2007–2009 | 15 | (25) | 15 | (25) | 0.00 |
| 2010–2013 | 45 | (75) | 45 | (75) | ||
| Use of PET | Yes | 30 | (50) | 31 | (52) | 0.03 |
| No | 30 | (50) | 29 | (48) | ||
| Use of systemic therapy | Yes | 10 | (17) | 13 | (22) | 0.13 |
| No | 50 | (83) | 47 | (78) | ||
| Previous cancer | Yes | 8 | (13) | 7 | (12) | 0.05 |
| No | 52 | (87) | 53 | (88) | ||
CFRT = conventional fractionated radiotherapy; PET = positron emission tomography; SABR = stereotactic ablative radiotherapy; sd = standard deviation;
Table 3
Patient characteristics in the second supplementary analysis
| SABR | CFRT | Standardized difference (rounded)* | ||||
|---|---|---|---|---|---|---|
| Number or mean (sd)* | (%)* | Number or mean (sd)* | (%)* | |||
| Age | 76.92 (8.84) | 77.73 (9.19) | 0.09 | |||
| Sex | Female | 8 | (31) | 7 | (27) | 0.09 |
| Male | 18 | (69) | 19 | (73) | ||
| Residency | Non-north | 16 | (62) | 18 | (69) | 0.16 |
| North | 10 | (38) | 8 | (31) | ||
| Comorbidity | Without | # | # | 0.13 | ||
| With† | # | # | ||||
| Histology | Adenocarcinoma | 14 | (54) | 15 | (58) | 0.08 |
| Non-adenocarcinoma | 12 | (46) | 11 | (42) | ||
| T stage | T1 | 11 | (42) | 11 | (42) | 0.00 |
| T2 | 15 | (58) | 15 | (58) | ||
| Use of PET | Yes | 13 | (50) | 12 | (46) | 0.08 |
| No | 13 | (50) | 14 | (54) | ||
| Use of systemic therapy | Yes | # | # | 0.13 | ||
| No | # | # | ||||
| Previous cancer | Yes | 3 | (12) | 3 | (12) | 0.00 |
| No | 23 | (88) | 23 | (88) | ||
| Performance status | ECOG (0–2) | # | # | 0.00 | ||
| ECOG (3–4) | # | # | ||||
CFRT = conventional fractionated radiotherapy; ECOG = Eastern Cooperative Oncology Group; PET = positron emission tomography; SABR = stereotactic ablative radiotherapy; sd = standard deviation; # Exact numbers are not reported because the Health and Welfare Data Science Center (HWDC) database center policy is to avoid numbers in single cells ≤ 2
Figure 3
Kaplan-Meier survival curve for the first supplementary analysis.
CFRT = conventional fractionated radiotherapy; SABRT = stereotactic ablative radiotherapy
Figure 4
Kaplan-Meier survival curve for the second supplementary analysis.
CFRT = conventional fractionated radiotherapy; SABRT = stereotactic ablative radiotherapy